Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 12/20 | 0.79 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.79 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6598550 | 0.88 | OPRD1 (1.00) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL6598891 | 0.85 | OPRD1 (0.58) | OPRD1OPRK1OPRM1ALDH1A1 | |
| SCHEMBL6598513 | 0.82 | OPRD1 (0.54) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598384 | 0.81 | OPRD1 (0.76) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6172131 | 0.79 | OPRD1 (0.83) | OPRD1OPRK1OPRM1CYP3A4CYP2D6 | |
| SCHEMBL7198825 | 0.77 | OPRD1 (0.53) | OPRD1OPRK1OPRM1 | |
| SCHEMBL1998734 | 0.77 | OPRD1 (0.65) | OPRD1OPRK1OPRM1 | |
| SCHEMBL1998738 | 0.77 | OPRD1 (0.65) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6598904 | 0.73 | OPRD1 (0.75) | OPRD1OPRK1OPRM1 | |
| SCHEMBL6265074 | 0.73 | OPRD1 (0.44) | OPRD1OPRK1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1140835-B1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PROD INC (US) | 2004-05-12 | — | — | EP | disclosed |
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | PFIZER INC | 2004-04-01 | — | — | US | disclosed |
| US-6503905-B1 | Treating nervous system and gastrointestinal disorders; analgesics, antiasthmatics | PFIZER INC | 2003-01-07 | — | — | US | disclosed |
| CN-1332727-A | 3, 3-diarylpiperidine and 2, 2-diarylmorpholine derivatives | PFIZER PROD INC (US) | 2002-01-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063940-A1 | 3,3-Biarylpiperidine and 2,2-biarylmorpholine derivatives | BCHE, HTR3C, CHRM2 | OPRD1 24/4885OPRK1 39/4885OPRM1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.